SAN DIEGO–(BUSINESS WIRE)– Tandem Diabetes Care, Inc. (NASDAQ:TNDM), a global insulin delivery and diabetes technology company, today announced that it has entered… Continue Reading
Articles
Vallon Pharmaceuticals and GRI Bio Enter into Merger Agreement with Goal of Advancing Innovative Pipeline of NKT Cell Regulators
PHILADELPHIA, PA and LA JOLLA, CA, Dec. 13, 2022 (GLOBE NEWSWIRE) — Vallon Pharmaceuticals, Inc. (NASDAQ: VLON), (“Vallon” or the “Company”),… Continue Reading
Merck Officially Commences $1.36B Imago Buyout
Merck is officially moving forward with a cash tender offer to buy all outstanding shares of South San Francisco-based Imago Biosciences, the larger company… Continue Reading
AEON Biopharma to Become Publicly Listed via Merger with Priveterra Acquisition Corp., Accelerating Clinical Development of ABP-450 (prabotulinumtoxinA) Injection to Treat Debilitating Medical Conditions in Neurology
Positive topline data from Phase 2 study of ABP-450 for cervical dystonia announced in September 2022. Topline data from Phase… Continue Reading
ZyVersa Therapeutics Inc. and Larkspur Health Acquisition Corp. Close Business Combination; ZyVersa Expected to Begin Trading on Nasdaq December 13, 2022 (Ticker “ZVSA”)
ZyVersa is a clinical stage biopharmaceutical company developing first-in-class product candidates for treatment of renal and inflammatory diseases WESTON, Fla…. Continue Reading
Amgen to Buy Horizon in Biotech’s Biggest Deal of 2022
Amgen has emerged the winner in a three-way contest to buy rare disease giant Horizon Therapeutics, confirming Monday morning it will acquire the Irish… Continue Reading
Myriad Genetics Patient Outcomes Study Shows RiskScore Leads to More Accurate Breast Cancer Risk Prediction than Standard-of-Care Risk Model
Myriad’s MyRisk™ Hereditary Cancer test with RiskScore® provides a personalized breast cancer risk assessment for women of all ancestries SALT… Continue Reading
Replimune Announces Pricing of Public Offering
BOSTON, Dec. 08, 2022 (GLOBE NEWSWIRE) — Replimune Group, Inc. (Nasdaq: REPL), a clinical stage biotechnology company pioneering the development of a… Continue Reading
Prometheus Biosciences, Inc. Announces Pricing of Public Upsized $500 Million Offering of Common Stock
SAN DIEGO, Dec. 08, 2022 (GLOBE NEWSWIRE) — Prometheus Biosciences, Inc. (Nasdaq: RXDX), a clinical-stage biotechnology company pioneering a precision medicine approach… Continue Reading
Dexcom Receives FDA Clearance for G7 Continuous Glucose Monitoring (CGM) System
What You Should Know: The FDA has cleared Dexcom G7 continuous glucose monitoring (CGM) system in the U.S. for people with… Continue Reading